David Green, the president of Harvard Bioscience, takes it personally when the company’s stock price takes a swan dive, like it did in May after the company announced disappointing first-quarter results.

He said that plunge cost him $10 million.

But, tell him that loss is only on paper, and the look you get will convince you of the pain he has incurred.

Green and Chane Graiziano acquired HBIO in 1996 and took it public in 2000, and today still hold some 18 percent of company stock.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

The Wall Street Journal looks into the cost of new gene therapies.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.